Compare GAUZ & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GAUZ | BLRX |
|---|---|---|
| Founded | 2009 | 2003 |
| Country | Israel | Israel |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.6M | 12.6M |
| IPO Year | 2019 | 2010 |
| Metric | GAUZ | BLRX |
|---|---|---|
| Price | $0.68 | $3.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $11.50 | ★ $19.00 |
| AVG Volume (30 Days) | ★ 40.2K | 14.7K |
| Earning Date | 05-12-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $22.59 | N/A |
| Revenue Next Year | $59.03 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.48 | $2.15 |
| 52 Week High | $10.01 | $7.77 |
| Indicator | GAUZ | BLRX |
|---|---|---|
| Relative Strength Index (RSI) | 46.47 | 73.89 |
| Support Level | $0.67 | $2.66 |
| Resistance Level | $0.88 | $3.11 |
| Average True Range (ATR) | 0.06 | 0.17 |
| MACD | -0.00 | 0.07 |
| Stochastic Oscillator | 12.66 | 91.80 |
Gauzy Ltd is a fully integrated light and vision control company. Its products include suspended particle device and liquid crystal materials for smart glass applications and AI-powered driver assistance systems, or ADAS, solutions including camera monitoring systems. The company's operating segments are Architecture, Automotive, Safety tech, and Aeronautics. Maximum revenue is generated from its Safety tech segment, which focuses on sales of driver assistance systems for buses, coaches, recreational vehicles, and specific vehicles, such as camera and motion sensor systems, smart mirrors, and safety doors. Geographically, it derives maximum revenue from other European countries (excluding France), followed by the United States, France, Asia, Israel, and other regions.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.